| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 16, 2004
From the Clinic for Small Animal Internal Medicine and Forensic Affairs (N.B., H.N., E.-G.G.), Faculty of Veterinary Medicine, Justus-Liebig-University Giessen; Department of Internal Medicine III (J.M.-E., N.H., C.Z., R.H.G.S.), University of Cologne, Germany; Department of Internal Medicine (U.K.), University of Tübingen; Institute of Biochemistry and Endocrinology (U.K., W.S.), Faculty of Veterinary Medicine, Justus-Liebig-University Giessen, Giessen, Federal Republic of Germany. * To whom correspondence should be addressed. E-mail: Wilhelm.Schoner{at}vetmed.uni-giessen.de.
Abstract--Ouabain, an inhibitor of the sodium pump, has been identified as a constituent of bovine adrenal glands. We were interested whether the release of this cardiotonic steroid is stimulated by physical exercise. Hence, athletes and healthy dogs were subjected to ergometry. Ouabain-like compound (OLC) was measured in venous blood by enzyme-linked immunosorbent assay as well as by 86Rb+ uptake inhibition (as ouabain equivalents). OLC increased in venous blood of athletes after 15 minutes of ergometry from 2.5±0.5 to 86.0±27.2 nmol/L (n=51; P<0.001), as did the concentration of a circulating inhibitor of the sodium pump from 7.3±1.7 to 129.8±51 nmol/L (ouabain equivalents, P<0.05). Half-maximal increase in heart rate and systolic blood pressure occurred at 5.1±1.2 nmol/L and at 30±1 nmol/L OLC, respectively. On rest, OLC decreased in humans and dogs with a half-life of 3 to 5 minutes. In beagles exposed to moderate exercise on a treadmill for 13 minutes, levels of OLC increased 46-fold (from 3.7±0.8 to 166.9±91.8 nmol/L; n=6; P<0.005). This effect was suppressed when the dogs had been treated for 3 weeks with the
Revised on October 7, 2004
Ouabain-Like Compound Changes Rapidly on Physical Exercise in Humans and Dogs. Effects of
Natali Bauer;
-Blockade and Angiotensin-Converting Enzyme Inhibition
1-adrenergic receptor blocker atenolol or the angiotensin-converting enzyme inhibitor benazepril. We conclude that OLC changes rapidly during exercise and is under the control of norepinephrine and angiotensin II.
-blocker
circulation
endogenous ouabain
hypertension
sodium pump hypertension
This article has been cited by other articles:
![]() |
M. Nesher, M. Dvela, V. U. Igbokwe, H. Rosen, and D. Lichtstein Physiological roles of endogenous ouabain in normal rats Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2026 - H2034. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Radzyukevich, J. B Lingrel, and J. A. Heiny The cardiac glycoside binding site on the Na,K-ATPase {alpha}2 isoform plays a role in the dynamic regulation of active transport in skeletal muscle PNAS, February 24, 2009; 106(8): 2565 - 2570. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Schoner and G. Scheiner-Bobis Role of endogenous cardiotonic steroids in sodium homeostasis Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2723 - 2729. [Full Text] [PDF] |
||||
![]() |
W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yoshika, Y. Komiyama, M. Konishi, T. Akizawa, T. Kobayashi, M. Date, S. Kobatake, M. Masuda, H. Masaki, and H. Takahashi Novel Digitalis-Like Factor, Marinobufotoxin, Isolated From Cultured Y-1 Cells, and Its Hypertensive Effect in Rats Hypertension, January 1, 2007; 49(1): 209 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Kotova, L. Al-Khalili, S. Talia, C. Hooke, O. V. Fedorova, A. Y. Bagrov, and A. V. Chibalin Cardiotonic Steroids Stimulate Glycogen Synthesis in Human Skeletal Muscle Cells via a Src- and ERK1/2-dependent Mechanism J. Biol. Chem., July 21, 2006; 281(29): 20085 - 20094. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Larre, A. Ponce, R. Fiorentino, L. Shoshani, R. G. Contreras, and M. Cereijido Contacts and cooperation between cells depend on the hormone ouabain PNAS, July 18, 2006; 103(29): 10911 - 10916. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dostanic-Larson, J. N. Lorenz, J. W. Van Huysse, J. C. Neumann, A. E. Moseley, and J. B Lingrel Physiological role of the {alpha}1- and {alpha}2-isoforms of the Na+-K+-ATPase and biological significance of their cardiac glycoside binding site Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R524 - R528. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Forni and W. Schoner Oabain-Like Compound Changes Rapidly on Physical Exercise in Humans and Dogs Hypertension, October 1, 2005; 46(4): e13 - e13. [Full Text] [PDF] |
||||
![]() |
Z. Yuan, T. Cai, J. Tian, A. V. Ivanov, D. R. Giovannucci, and Z. Xie Na/K-ATPase Tethers Phospholipase C and IP3 Receptor into a Calcium-regulatory Complex Mol. Biol. Cell, September 1, 2005; 16(9): 4034 - 4045. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.J. Hilton, W. McKinnon, and W. Schoner Radioimmunoassays, Ouabain-Like Material, and Ouabain * Response Hypertension, September 1, 2005; 46(3): e9 - e10. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |